Sagimet Biosciences Inc.
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $2.0M
- Net income
- -$51.0M
- Total assets
- $116.5M
- Market cap
- $417.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $56.9M
- Operating income
- -$56.9M
- Income tax
- $0
- Net income
- -$51.0M
- EPS (basic)
- $-1.58
- EPS (diluted)
- $-1.58
Balance sheet
- Total assets
- $116.5M
- Current assets
- $116.4M
- Total liabilities
- $5.1M
- Current liabilities
- $5.1M
- Shareholders’ equity
- $111.4M
Cash flow
- Operating cash flow
- -$45.6M
- Investing cash flow
- $4.6M
- Financing cash flow
- $275.0K
- Net cash flow
- -$40.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $417.4M
- EPS (diluted)
- $-1.58
- Shares outstanding
- 63.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 14, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $51.0M in FY2023.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sagimet Biosciences Inc..
Write a review
News about Sagimet Biosciences Inc.
News & sentiment via Polygon.io
